All companies
Dong-A Pharmaceutical logo

What smart money is saying about Dong-A PharmaceuticalSouth Korea flag

000640.KS · Healthcare · Drug Manufacturers - Specialty & Generic · Market cap $424M

1 fund in our archive has pitched Dong-A Pharmaceutical, most recently Terton Capital Fund in November 2026.

Company profile

Dong-A Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the pharmaceutical business in South Korea. It operates through a Holding Company; Over-the-Counter Drugs and Quai-Drugs; Biosimilars and Consignment Medicines; Logistics; Packaging Solutions; and Others segments. The company develops DA-8010 in Phase 3 clinical trial to treat overactive bladder; DMB-3115, a biosimilar of Stelara in Phase 3 clinical trial; DA-1241 in Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis; DA-1726 in Phase 1 clinical trial to treat obesity; and STP0404 for the treatment of AIDS. It also provides medical devices and equipment; healthcare solutions to customers in Bacchus, over-the-counter, consumer healthcare, and cosmetics; health functional food; contract development and manufacturing organization for biosimilar and pharmaceutical products, and oligonucleotide therapeutics; functional sports drinks under the POCARI SWEAT brand; logistics and fulfillment services; glass bottles, PET bottles, aluminum and plastic caps, and paper packaging boxes; mineral and carbonated water, and mixed drinks; and IT and construction services. In addition, the company is involved in engineering; cargo, courier, and automobile transport arrangements; transportation warehousing and leasing; real estate development; agricultural product distribution; management consulting; business management; and architectural, electrical work, fire protection, and housing contracting services. The company was formerly known as Dong-A Socio Holdings Co., Ltd. and changed its name to Dong-A Pharmaceutical Co.,Ltd. in October 2026. Dong-A Pharmaceutical Co.,Ltd. was founded in 1932 and is headquartered in Seoul, South Korea.

Get an email when a fund buys, sells or pitches it

Summarize with Warren AI
1
Reported positions
0
Bought
0
Sold
1
Letter

Position history

Every position in Dong-A Pharmaceutical on record in the archive was reported in Q4 2026, across 1 fund letter, with no move described.

Fund letters reporting a position in Dong-A Pharmaceutical, by quarter
QuarterLettersBoughtSoldTheses
Q4 20261001

Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.

Fund activity · 1 position

  • HoldsTerton Capital Fund
    November 2026
    “Dong-A Pharmaceutical • Dong-A Pharmaceutical (formerly Dong-A Socio Holdings) owns some of the best assets in Korean healthcare. This includes a Bacchus-led (the Korean Red Bull) consumer health business that has earned a ~12% operating margin and an ROE above 30% in each of the past twelve years11, and a 29.2% stake in ST Pharm, one of the few companies in the world qualified to manufacture oligonucleotide medicines.12 At the November 6 close, its stakes in ST Pharm and Dong-A ST alone were worth 91% of its market cap.13 We estimate fair value at about three times the share price.14 • The discount is due to governance issues. The Chairman leads the group without sitting on the Board or standing for election 15 , all 27 capital allocation resolutions passed without a dissenting vote 16 , and capital and debt guarantees have gone to affiliates such as BTGEN.17 From April 2013 to November 6, 2026, Dong-A returned 1.9% including dividends, against 238.5% for the KOSPI.18 • We wrote privately to the Board on October 12 and October 26.”
    Dong-A Pharmaceutical

Fund coverage · 1 thesis

  • Terton Capital Fund
    November 2026

    Dong-A Pharmaceutical holds a high-margin Bacchus consumer health business and a 29.2% stake in ST Pharm, with listed stakes alone worth 91% of market cap and fair value estimated at about three times the share price, while governance failures explain the discount.

    Read the full thesis

Read every full thesis on Dong-A Pharmaceutical

Read all 1 thesis in full, with each fund's reasoning, and get unlimited access to the archive.

View plans→
Share this ledger